KalVista Pharmaceuticals (KalVista Pharmaceuticals) 3-Year RORE % : 1.23% (As of Jan. 2024)

KalVista Pharmaceuticals 3-Year RORE % Chart

KalVista Pharmaceuticals Annual Data
	Trend	Dec14	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
3-Year RORE %		Get a 7-Day Free Trial					-54.42	1.71	18.17	23.24	10.53

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
3-Year RORE %	Get a 7-Day Free Trial															16.63	10.53	7.68	4.12	1.23

Competitive Comparison of KalVista Pharmaceuticals's 3-Year RORE %

For the Biotechnology subindustry, KalVista Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's 3-Year RORE % falls into.

KalVista Pharmaceuticals 3-Year RORE % Calculation

KalVista Pharmaceuticals's 3-Year RORE % for the quarter that ended in Jan. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jan. 2024 and 3-year before.

KalVista Pharmaceuticals  (NAS:KALV) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.

KalVista Pharmaceuticals 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (KalVista Pharmaceuticals) Business Description